PHGDH and lung adenocarcinoma: In EGFR mutation-positive lung adenocarcinomas, downregulation of PHGDH or treatment with a PHGDH inhibitor increased ROS stress and DNA damage, ultimately sensitizing cells to receptor tyrosine kinase inhibitors (erlotinib) [87].